CLINICAL OUTCOMES OF USE OF HYDROXYCHLOROQUINE IN PARADOXICAL TUBERCULOSIS-IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV-INFECTED PATIENTS. by A, Pramod Kumar et al.
Vol 11, Issue 2, 2018
Online - 2455-3891 
Print - 0974-2441
CLINICAL OUTCOMES OF USE OF HYDROXYCHLOROQUINE IN PARADOXICAL 
TUBERCULOSIS-IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN  
HIV-INFECTED PATIENTS
PRAMOD KUMAR A1, PARTHASARATHI G1*, MOTHI SN2, SUDHEER AP2, VHT SWAMY2, SRI RAMA2
1Department of Pharmacy Practice, JSS College of Pharmacy, JSS University, Mysore, Karnataka, India. 2Department of Infectious Diseases, 
Asha Kirana Hospital, Centre for AIDS Care and Research Center, Mysore, Karnataka, India. Email: gparthasarathi@jssuni.edu.in
Received: 14 August 2017, Revised and Accepted: 15 November 2017
ABSTRACT
Objective: Immune reconstitution inflammatory syndrome (IRIS) is an inflammatory reaction in HIV-infected patients after initiation of antiretroviral 
therapy (ART) resulting from restored immunity to specific infectious or non-infectious antigens. The most common condition where IRIS has been 
reported is tuberculosis (TB). Various mechanisms have been proposed and studied to account for the immune regulatory role of hydroxychloroquine 
(HCQ). This study is done to identify clinical outcome in HIV-TB patients with IRIS after given with HCQ.
Methods: An uncontrolled longitudinal study was conducted among HIV-infected patients with TB initiated on ART and developed IRIS between July 
2013 and June 2015 in a South Indian HIV care hospital.
Results: A total of 40 patients have developed IRIS with mean age of 35.87 years and 77.5 % of them were males. At the time of IRIS occurrence, the 
mean body mass index was found to be 19.17 kg/m2 and CD4 count was 200 cells/mm3. The time duration took to get improvement in majority of the 
patients was 4–12 weeks.
Conclusion: There was definite improvement seen in patients who received HCQ in TB-IRIS condition.
Keywords: Hydroxychloroquine, Immune reconstitution inflammatory syndrome, HIV, Tuberculosis.
INTRODUCTION
The benefits of antiretroviral therapy (ART) in improving survival, 
reducing morbidity, and enhancing the quality of life in HIV-infected 
patients have been widely demonstrated. However, during the early 
period of immune restoration with ART, immune reconstitution 
inflammatory syndrome (IRIS) develops in a subset of patients 
(15–25%). IRIS manifests as clinical deterioration resulting from 
ART augmented immune responses that cause inflammation 
in tissues directed at infective, or less frequently, non-infective 
antigens. The clinical presentation of IRIS varies, with comorbidities 
associated with it. The etiology of IRIS is unknown but thought to 
be a reactivation of suppressed immune system after profound 
suppression by the HIV [1].
IRIS, a life-threatening condition, presents challenges to the clinicians in 
terms of diagnosis and management as there is lack of proper diagnostic 
tests and evidence-based guidelines for the management [2,3]. Infective 
IRIS results from an inappropriate or dysregulated immune response 
directed to pathogen-specific antigens. Essentially, any pathogen that 
can cause an opportunistic infection, as a result of impaired cellular 
immune responses can provoke IRIS after pathogen-specific immune 
responses are restored by ART. Most cases occur within the first 
3 months of starting ART, coinciding with a rapid rise in peripheral 
blood CD4+ cells. Mycobacterial and fungal forms of IRIS usually 
present with features of T-helper 1 immune response, manifesting 
with granulomatous inflammation, or suppuration. In contrast, CD8+ 
T-cells are the dominant inflammatory cells found in IRIS related to 
viruses [4,5].
To date, no prospective therapeutic trials concerning the 
management of IRIS have been conducted. All evidence regarding 
the management of IRIS in the literature relates to case reports 
and small case series reporting on management practice. Majority 
of patients with IRIS have a self-limiting disease course. Mortality 
associated with IRIS is relatively uncommon; however, associated 
with high morbidity places considerable burden on the health-
care system. Morbidity and mortality rates vary according to the 
pathogen and organs involved [6,7].
The antimalarial drug hydroxychloroquine (HCQ) is endowed with 
immune modulatory effects including the reduction of inflammatory 
cytokine production and of immunoglobulin (IgG) levels, and a 
down-modulation of natural killer cell activity; these properties have 
warranted its use in some of the autoimmune conditions [8]. HCQ is 
used in the treatment of various inflammatory disease conditions, and 
short-term HCQ is generally well tolerated at a dosage of 400 mg/day. 
Based on these findings, data exploration was performed from PubMed 
and Scopus databases using the search terms HCQ, HIV management, 
and paradoxical tuberculosis (TB)-IRIS. The search conducted did 
not cite any relevant published literature, where HCQ is tried to treat 
the HIV patients with TB-IRIS. Hence, this study was conducted to 
understand the efficacy of short-term HCQ use in the treatment of 
paradoxical TB-IRIS condition.
METHODS
A prospective uncontrolled longitudinal study was conducted at an 
HIV care hospital, Mysore, India, between July 2013 and June 2015. 
The study was approved by the Institutional Ethical Committee of 
study site hospital. HIV-infected patients who developed paradoxical 
TB-IRIS during the study were included in the study. The TB-IRIS 
was defined as per the International Network for the Study of HIV-
associated IRIS (INSHI) criteria - (INSHI; World Health Organization; 
ART) (Table 1). The data regarding the concurrent use of other drugs, 
laboratory values, opportunistic infections, and other prescribed 
drugs to any other disease condition were collected from the medical 
records and treating physician notes. Patients were given with HCQ 
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200 mg/day for a maximum period of 6 months and were followed 
up at every 15 days for the measurement of treatment outcomes and 
IRIS progression condition. The data collected were entered into a 
specially designed excel sheet for easy retrieval of data and analysis. 
Categorical variables were described using relative frequencies; 
whereas the standard deviation and mean were used for continuous 
variables. All analyses were carried out using SPSS software 
version 21.0.
RESULTS
A total of 40 patients were included in the study. All patients were given 
with HCQ and followed for the clinical outcomes. The mean age of the 
patients was found to be 35.87 (±8.54), mean CD4 count was 200 (±263), 
and mean body mass index was 19.17. The patient’s characteristic is 
further detailed in Table 2. The ART regimens involved in the study 
population and the duration of time for the occurrence of IRIS is 
detailed in Table 3. INSHI criteria of patients show that patients with 
one major criteria are 30 (75%), one major and one minor are 6 (15%), 
one major and two minor are 2 (5%), and two minor are 2 (5%). Of 
the 40 patients, IRIS symptoms improved in 33 patients, and mainly 
observed as decreased lymphadenopathy (enlarged lymph nodes) 
among the patients with major criteria and decreased worsening of 
constitutional symptoms (headache and fever) among the patients with 
minor criteria with an overall recovery rate of 82.5%.
DISCUSSION
Data from in vitro study, as well as results obtained in the murine model, 
have shown that HCQ also modulates the intracellular toll-like receptor 
(TLR) pathway as it also reduces the production of interferon gamma, 
tumor necrosis factor-α, and interleukin 6. Notably, HCQ decreases 
Tat-mediated transactivation of HIV-1 TLR in vitro as well-thereby 
decreasing HIV-1 production and alters the immunogenic properties of 
gp120 [9]. Based on these findings, the use of HCQ has been evaluated 
in HIV infection. Results showed that decreases in viral load, IL-6, and 
serum IgG titers, as well as a reduction of immune activation and a 
decrease of CD38+CD8+ T-cell and Ki-67 memory CD4+ T-cells can be 
observed in HIV-infected patients receiving HCQ.
The effect of this compound on these immune parameters is important 
given the fact that immune activation is believed to play a key 
role in HIV pathogenesis. This suggestion stems from a number of 
observations [10]. Thus, the massive destruction of CD4+ T-cells in the 
gastrointestinal mucosa observed in the initial phases of the infection 
would provoke severe mucosal alterations. These observations led 
to therapeutic approaches based either on therapy intensification or 
immunomodulation that, nevertheless, did not result in any significant 
effect. Based on these observations and on the ability of HCQ to 
downregulate TLR-mediated activation, this compound has an effect on 
immune modulation in HIV-infected IRIS individuals [11].
Systemic corticosteroids or non-steroidal anti-inflammatory agents 
are used to alleviate the symptoms of IRIS [12,13]. There are no 
standard guidelines recommending the defined dosage regimen of 
these agents in the treatment of IRIS. Often, the dosage regimen and 
choice of anti-inflammatory agents used depends entirely on personal 
experience of treating physicians. Hence, the therapeutic outcomes are 
variable. These practices reflect the lack of evidence from controlled 
trials for the use of anti-inflammatory agents in IRIS [11]. HCQ has 
established immunomodulatory effects, and due to its relatively low 
and well-established side effects, the drug may be potentially useful 
in IRIS patients. However, to rationalize the therapeutic usefulness, 
Table 1: INSHI criteria
A. Antecedent requirements (both criteria 
must be met)s
B. Clinical criteria (one major criterion or two minor 
clinical criteria are required)
C. Alternative explanations 
must be excluded if 
possibleMajor criteria Minor criteria
Diagnosis of tuberculosis: The diagnosis of 
tuberculosis made before starting ART (WHO 
criteria)
New or enlarging lymph 
nodes, cold abscesses, 
or other focal tissue 
involvement
New or worsening 
constitutional symptoms
Tuberculosis drug resistance, 
poor adherence to treatment, 
drug toxicity, and another 
opportunistic infection
Initial response to tuberculosis treatment: Initial 
improvement or stabilization on appropriate 
anti-TB treatment before ART initiation (however, 
in patients starting ART within 2 weeks of 
starting tuberculosis treatment, insufficient time 
may have elapsed for a clinical response to be 
reported)
New or worsening 
central nervous system 
tuberculosis
New or worsening respiratory 
symptoms
New or worsening 
radiological features of 
tuberculosis
New or worsening abdominal 
pain accompanied by 
peritonitis, hepatomegaly, 
splenomegaly, or abdominal 
adenopathy
New or worsening 
serositis
ART: Antiretroviral therapy, WHO: World Health Organization
Table 2: Patient characteristics
S. No. Category Characteristic 
properties
Total (%) Recovered
1 Age <40 years 27 (67.5) 23
41–60 years 11 (27.5) 9
>61 years 2 (5) 1
2 Gender Male 31 (77.5) 27
Female 9 (22.5) 6
3 BMI (Kg/m2) <20 18 (45) 16
21–25 20 (50) 16
>25 2 (5) 1
4 CD4 CD4 
count (cells/ml)
<200 4 (10) 2
>200 36 (90) 31
5. Type of TB TB-lymphadenitis 30 (75) 25
Pulmonary-TB 6 (15) 4
Abdominal-TB 4 (10) 4
BMI: Body mass index, TB: Tuberculosis
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Table 3: ART regimen responsible for IRIS
Category Regimen Number of patients (%)





Time duration for improvement (weeks) 1–4 17
4–12 11
12–24 5
Time duration between ART initiation and IRIS occurrence (weeks) 1–4 22 (55)
4–12 13 (32.5)
12–24 5 (12.5)
ART: Antiretroviral therapy, IRIS: Immune reconstitution inflammatory syndrome
further studies are necessary, as there are currently insufficient data to 
recommend HCQ in the management of IRIS.
CONCLUSION
Our observation suggests that prompt recognition of early symptoms 
of paradoxical TB-IRIS and short-term HCQ may be useful in the 
management of paradoxical TB-IRIS.
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